Sanket Koul

Signature Global enters senior living with Manasum, eyes ₹575 cr sales

The companies will develop 164 senior living units at Sarvam DXP in Gurugram, with prices starting at around Rs 3.7 crore per unit and handover expected in 48 months

Centre's cancer drug margin cap draws mixed response from industry, groups

The NPPA's 30% trade margin cap on 137 oncology drugs, effective November 9, has drawn support from the pharma industry, while patient groups question its impact on affordability.

Centre finalises 30% trade margin cap for 137 non-scheduled cancer drugs

New prices set to come into effect from November 9, 2026; state drug controllers to monitor implementation

Paras Health to use ₹375 cr from IPO to pare debt, plans 800-bed expansion

The ₹1,450-crore IPO comprises a ₹500-crore fresh issue and a ₹950-crore offer for sale, while the hospital chain plans to add 800 beds through projects in Gurugram and Ludhiana

CDSCO waives export NOC for approved r-DNA drugs sold under new brand names

The move is expected to reduce export approval timelines for biologics manufacturers using different brand names in overseas markets, provided the products are already approved in India

Centre directs states, UTs to display health service charges at all clinics

Union Health Ministry seeks prominent display of healthcare service charges and package rates for foreign patients travelling to India on medical or Ayush visas to improve transparency.

SC asks why drug price caps cannot extend beyond cancer medicines

Bench questions steep mark-ups on medicines and medical devices; Centre says price regulation must balance affordability with availability

After cancer drugs, medtech firms seek uniform trade margin cap for devices

Domestic manufacturers want importers' margins included in a uniform trade margin framework for medical devices, with a pilot covering high-volume consumables such as IV sets

Centre to cap trade margins on non-scheduled cancer drugs at 30%

Move could cut MRPs by up to 70%, save patients ₹2,500 crore annually; comes amid SC scrutiny of high mark-ups

IPM volume growth at 3.4% marks 2-yr high on steady demand across therapies

Volume growth reached 3.5 per cent, the highest in two years, while pricing rose about 6.2 per cent as most therapy segments recorded stronger demand

State scrutiny of pharma price mark-ups may lead to review of TMR policy

Drug regulators in Maharashtra, Karnataka and Uttar Pradesh are gathering data on price mark-ups, potentially strengthening the case for a review of trade margin rationalisation

DLF completes sell-out in its senior living project for ₹1,985 crore

All 172 four-bedroom units at DLF's Aureva project in Gurugram were sold at an average ticket price of ₹11.5 crore, with NRIs accounting for 25 per cent of buyers

Affluent seniors are turning metros into luxury retirement addresses

Rising affluence, longer life expectancy and changing family structures are drawing mainstream developers to premium senior living projects in India's major urban markets

Drug regulator may review machinery disposal at non-compliant pharma units

The Drugs Consultative Committee has sought a detailed proposal from Rajasthan amid concerns that machinery from closed pharma units could be used to make spurious drugs

CDSCO seeks DGHS view on exemptions for mercury-based topical antiseptics

The Drugs Consultative Committee has sought the DGHS opinion and data on Merbromin's manufacture and use before deciding on its continued inclusion under Schedule K

Pharma dept to offer gap funding for early-stage novel drug discovery

Funding will be part of a new track under the PRIP scheme exclusively for start-ups and MSMEs at the initial research stage, with assistance of up to ₹50 crore per project

Following SC order on forensic audit, IHH may raise Fortis stake to 51%

IHH says India remains a key strategic market as it plans to deepen its Fortis investment, despite a Supreme Court-ordered forensic audit into past transactions

'This is carnage': SC flags high drug prices, moots 16% margin cap

A Bench of Justices Vikram Nath and Sandeep Mehta asked the Centre why the maximum retail price (MRP) of essential medicines such as cancer drugs could not be capped at 16 per cent

Supply constraints support premium office rents in Mumbai, Delhi-NCR

Consultants attribute premium rentals in key micro-markets to limited quality Grade A space and sustained occupier demand, even as rents vary significantly across locations

Medtech firms, hospitals back TMR amid medical device mark-up debate

Medtech manufacturers and private hospitals back trade margin rationalisation but seek a fact-based approach that accounts for category-specific costs and procurement structures